Evaluation of the potential food allergy risks of human lactoferrin expressed in

Prior to the introduction of novel food ingredients into the food supply, safety risk assessments are required, and numerous prediction models have been developed and validated to evaluate safety. The allergenic risk potential of Helaina recombinant human lactoferrin (rhLF, Effera™), produced in The literature search identified no allergenic risk for Helaina rhLF, Collectively, these results demonstrate a low allergenic risk potential of Helaina rhLF and do not indicate the need for further clinical testing or serum IgE binding to evaluate Helaina rhLF for risk of food allergy prior to introduction into the food supply.

Informations de copyright

Copyright © 2024 Anaya, Rosario Martinez, Goodman, Johnson, Vajpeyi, Lu, Peterson, Weyers, Breen, Newsham, Scottoline, Clark and Malinczak.

Déclaration de conflit d'intérêts

Authors YA, RR, SV, XL, BB, KN, RP, AC, and C-AM are all employees of Helaina, Inc. RG is an employee of RE Goodman Consulting. Corresponding author C-AM is a review editor for Frontiers in Immunology. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.